VALDA: Volatile Associated Liver Disease Audit

Not Applicable

• Conditions: The incidence of liver disease caused by exposure to volatile anaesthetic agents, in trauma patients.; Anaesthesiology - Anaesthetics; Oral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon; Inflammatory and Immune System - Allergies

• Registration Number: ACTRN12612000286842
• Lead Sponsor: Brad Hockey

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-03-12
• Last Update Posted: 13 January 2020

Recruitment & Eligibility

• Status: ot yet recruiting
• Sex: All
• Target Recruitment: 500

Inclusion Criteria

Trauma patients admitted to Royal Melbourne Hospital.

Exclusion Criteria

No consent.

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Incidence of liver disease attributable to volatile agent exposure, as determined by previously mentioned data. Patients with abnormal over function will be further for concomitant hepatotoxic medications and liver injury. Those suspicious of VALDA will have anti-TFA antibody screening to confirm it.[Development of VALDA within 12 days of exposure.]

Secondary Outcome Measures

Name	Time	Method
Incidence of liver disease in trauma patients, as determined by abnormal liver function tests.[Within twelve days of surgery.]